The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
18
The invervention comprises 3 Groups: * Group 1: Low Dose * Group 2: Middle Dose * Group 3: High Dose
St. David's Medical Center
Austin, Texas, United States
RECRUITINGFrequency of adverse events
Time frame: Day 1 to 36 weeks PMA(post menstrual age)
Pharmacokinetic parameters of FLQ-101
Time frame: Day 1 to 24 hours post first oral dose
Pharmacodynamic parameters of FLQ-101
Time frame: Day 1 to 24 hours post first oral dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.